The prevalence of hepatitis C virus (HCV) antibodies in Croatia is low in the general population (reported <1%), similar to the prevalence rates of many European countries, but is higher in the populations at risk, especially among intravenous drug users. With the development of new classes of direct-acting antiviral agents and interferonfree regimens, the landscape of HCV treatment has completely changed. Management of HCV infection in Croatia is in accordance with the European Association for the Study of the Liver (EASL) recommendations published in 2015, recently updated Croatian Guidelines (published in April 2016) and the recommendations of Croatian Health Insurance Fund (HZZO) which covers the costs of treatment. HZZO approved simeprevir at the beginning of 2015. By the end of the 2015 sofosbuvir, combination of sofosbuvir + ledipasvir and the combination of ombitasvir, paritaprevir and ritonavir ± dasabuvir became available. Although the drawback of these new highly effective treatments is their price, prioritization of patients on a national level offers equal opportunities to patients in need for treatment. Due to improvements in therapy and prevention, clinical care for patients with HCV in Croatia advanced significantly during the last two years.
Introduction
The prevalence of hepatitis C virus (HCV) antibodies in Croatia is low in the general population (reported <1%). HCV seroprevalence in the Croatian adult general population is similar to the prevalence rates of many European countries (for example Spain, France, Belgium, Poland, and Bulgaria) [1] [2] [3] [4] [5] . In comparison with other European countries, there have also been changes in the HCV epidemiology in Croatia over the past few decades. According to the published data, the estimated number of HCV-infected patients in Croatia is around 39,000, although the experts' opinion is that the real numbers are significantly smaller [6, 7] . There was no significant difference in the HCV seropositivity between males and females in the Croatian population, with the highest prevalence in the 30-39 age group (1.7%) [8] . Routine HCV screening of blood products was introduced in Croatia in 1992.
The prevalence of HCV infection in some population groups in Croatia is shown in Table 1 [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Patients requiring multiple transfusions have a high prevalence of HCV infection, but with the implementation of mandatory anti-HCV and HCV RNA screening of blood/ blood donations, the risk of transfusion-associated hepatitis C has virtually been eliminated. [22] . HCV seroprevalence in the Croatian pregnant women is comparable to data reported in Switzerland and Spain [23, 24] . In this population, injecting drug users (IDU), history of blood products transfusion before 1992 and hospitalization with surgical procedures were identified as most common risk factors [25] . Since blood donors represent a strictly controlled group, it is expected that the HCV prevalence is lower than in the general population [26] . There are no published data on the HCV prevalence in the Croatian healthcare workers who have sustained contaminated needle stick injuries (occupationally exposed groups) [27] .
Prevalence of HCV genotypes in Croatia varies by different population groups and regions.
The prevalence of genotypes in Croatian population is shown in Table 2 . In the general population, genotype 1 is the most widely distributed, while genotype 3 is predominant among IDUs. The most commonly detected subtype is 1b and it is predominant in hemodialysis patients. In prison population, genotype 1 and 3 are equally distributed and similar Update on Hepatitis C genotype distribution is found in groups with high-risk sexual behavior [28] [29] [30] [31] . Similar pattern of genotype distribution is found in other European countries, where genotypes 1 and 3 also account for the majority of HCV infections with the most frequent subtype 1b [32] . The prevalence of genotype 4 is rising in Europe (in countries such as France, Germany, Greece, Italy, Poland, Portugal, Spain, Sweden, and Switzerland) due to immigration in these areas [33] . There are some differences comparing EASL and Croatian Guidelines, which are listed as fol- 
Indications for treatment in Europe and Croatia

Therapeutic protocol
The goal of therapy is to cure HCV infection to prevent hepatic cirrhosis, decompensation of cirrhosis, hepatocellular carcinoma, severe extrahepatic manifestations, and death. The endpoint of therapy is undetectable HCV RNA in blood by a sensitive assay 12 weeks (SVR12sustained virologic response) and/or 24 weeks (SVR24) after the end of treatment [37] . sated cirrhosis, the only treatment option currently available is the combination of sofosbuvir and ledipasvir with ribavirin for 12 weeks or without ribavirin for 24 weeks. This is also the only available option for patients previously treated with the triple combination of PegIFN + ribavirin + first-generation PIs (boceprevir or telaprevir) (in Croatia, there are only a few patients that have not responded to treatment with new-generation DAAs, as they have recently become available). According to EASL, experienced, DAA-naive patients with genotype 1b with or without compensated cirrhosis should be treated with fixed-dose combination of sofosbuvir and ledipasvir without ribavirin, and with ribavirin in those patients with genotype 1a. In EASL Guidelines, for the treatment of naive and experienced patients with genotype 1, there are two more options (not available in Croatia): fixed-dose combination of sofosbuvir and velpatasvir without ribavirin, ritonavir-boosted paritaprevir, ombitasvir and dasabuvir with or without ribavirin, grazoprevir and elbasvir with or without ribavirin, and sofosbuvir and daclatasvir with or without ribavirin.
For the treatment of patients with genotype 4, the same recommendations as for genotype 1 apply, with the exception of fixed combination of ombitasvir, paritaprevir, and ritonavir, which is used without dasabuvir. In patients with cirrhosis, duration of treatment is 24 weeks.
In EASL Guidelines, for the treatment of these patients, there are few more options available: sofosbuvir and velpatasvir without ribavirin, grazoprevir and elbasvir with or without ribavirin, and sofosbuvir and daclatasvir with or without ribavirin.
For the treatment of naive patients with genotype 2, with F1-F3 fibrosis, the use of standard 
Croatian Health Insurance Fund (HZZO)-reimbursement requirements
Croatian Health Insurance Fund (HZZO) is covering over 99% of the population. HCV treatments are funded from a separate budget for expensive medicines [39] . HZZO has listed conditions that patients have to fulfill in order for HCV treatment to be covered from the before-mentioned fund: age between 18 and 70 years, HCV RNA positive, with a specified genotype, histologic evidence of chronic inflammation (biopsy finding) or fibroscan result larger than 8 kPa, and abstinence of IDU and significant alcohol consumption for the past 12
months. In patients with normal alanine aminotransferase (ALT) level, treatment is indicated with fibrosis F ≥ 2 or fibroscan finding >8 kPa. Patients who are IDUs need to have evidence of abstinence from illegal substances for at least one year and documented psychiatrist's finding and results of toxicology testing every 3 months during medical treatment. Treatment reimbursement requirements in Croatia include: specialist recommendation for treatment, Hospital's drug committee approval, and request for treatment sent to Expert committee for the treatment of hepatitis C of HZZO for final approval of treatment modality and duration (respect priorities among patients). All other Croatian patients with chronic hepatitis C (not fulfilling the above-mentioned requirements) can also be treated based on the judgment of the treating physician, but with a more restricted reimbursement options.
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Conclusion
Regarding improvements in therapy and prevention, clinical care for patients with HCV in Croatia has advanced significantly during the past two years. Comparing epidemiology, indications for the treatment, available drugs, and therapeutic protocols, it is clear that Croatia accompanies European trends in HCV treatment. In future, rapid changes in the treatment of chronic HCV infection with the innovation of new drugs will lead to more effective, shorter treatment courses and PegIFN-free modalities. 
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